Using the OHD4–12, we demonstrate that it interrupts the CXCL12-driven migration of breast cancer cells, thus establishing the role of CXCL4–CXCL12 heterodimer in breast cancer and suggesting its utility for therapeutic advantage. This evidence concerns the gene PF4 and breast carcinoma.